1. ESSENTIAL CONCEPTS IN THE USE OF SOMATOSTATIN ANALOGUES IN PATIENTS WITH NEUROENDOCRINE TUMORS

2. Program Goals

3. Program Outline

4. History of Carcinoid Tumors

5. Features of NETs

7. Incidence of NETs Over Time by Primary Site

8. Are NETs Really That "Rare"?

9. Patient Characteristics That Affect Treatment Selection

12. Pathology (Ki-67)

13. Other Classification and Nomenclature Systems

16. Treatment Characteristics that Affect Treatment Selection (cont)

17. SSAs May Play Various Roles in the NET Treatment Algorithm

18. SSAs Are Mainstay of Treatment for Controlling Hormones

19. SSAs Also Have a Role in Controlling Tumor Growth

20. Physiology of Somatostatin and SSAs

21. Tools Used for Hormone Control

22. ELECT Trial: Randomized Trial of Lanreotide for Carcinoid Syndrome

23. General Principles of SSA Dosing For Hormone Control

24. Tools for Tumor Control in NETs

25. PROMID: Octreotide LAR for Tumor Control in Metastatic Midgut NETs

26. CLARINET: Antitumor Effects of Lanreotide in Metastatic NETs

27. Key Features of PROMID vs CLARINET

28. Principles of SSA Dosing For Tumor Control

29. COOPERATE-2: Everolimus ± Pasireotide in Advanced Pancreatic NETs

30. Peptide Receptor Radionuclide Therapy

31. NETTER-1: Peptide Receptor Radionuclide Therapy

32. Conclusions

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)

36. Abbreviations (cont)

37. References

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)

43. References (cont)